<DOC>
	<DOCNO>NCT00251251</DOCNO>
	<brief_summary>Congestive heart failure ( CHF ) common health problem lead frequent hospitalization increase death rate . In spite advance drug therapy , remain significant public health problem . Recently , new therapy develop advanced heart failure patient ventricular conduction abnormality . This new therapy , call cardiac resynchronization ( CRT ) , device stimulates atrium , right ventricle , leave ventricle provide synchronization contraction heart chamber . It addition therapy implantable cardioverter defibrillator ( ICD ) evaluate study . This study compare whether implantation new therapy device , combination implantable cardioverter defibrillator , reduce total mortality hospitalization CHF .</brief_summary>
	<brief_title>Resynchronization/Defibrillation Ambulatory Heart Failure Trial</brief_title>
	<detailed_description>Cardiovascular mortality decrease industrial country , however mortality congestive heart failure increase . The important predictor mortality heart failure patient depress left ventricular function , severity symptom ( NYHA class ) , ventricular conduction abnormality manifest wide QRS . Recent advance pharmacological therapy include ACE inhibitor , beta-blocker spironolactone result improvement symptom reduction mortality . Population epidemiological study demonstrate mortality hospitalization rate heart failure remain high despite recent pharmacological therapeutic progress . Recent short-term clinical trial demonstrate cardiac resynchronization therapy ( CRT ) effective improving symptom heart failure , functional capacity quality life patient moderate severe heart failure conduction abnormality optimally treat drug therapy . However , data morbidity mortality mild moderate heart failure lack . The objective trial determine addition CRT optimal pharmacological therapy ICD effect reduce mortality morbidity patient poor LV function , wide QRS mild moderate heart failure symptom . This double-blinded randomized control trial . A total 1800 patient mild moderate heart failure symptom , LVEF ≤ 30 % , QRS ≥ 120 m include study . Patients randomize either `` ICD plus Optimal Medical Therapy ( control ) '' `` CRT/ICD plus Optimal Medical Therapy ( experimental ) '' 1:1 randomization ratio . Patients control group implant single dual chamber ICD . Patients experimental group receive device capability CRT ICD . Optimal Medical Therapy include ACE inhibitor beta-blockers . Patients follow regular basis clinical evaluation , quality life assessment , six minute walk test perform . The primary outcome composite total mortality heart failure hospitalization . Secondary outcome measure include total mortality , cardiovascular mortality , sudden arrhythmic death , health relate quality life cost economics . Patient accruement schedule 4.5 year minimum follow 18 month . DFT sub study : Overview sub-study Design Patients participate RAFT trial , participate site , randomize DFT test test time device implant . Up 450 patient eligible enrollment Canadian European centre . The study two primary outcome : short-term safety outcome long-term efficacy outcome . The safety outcome composite adverse event potentially relate DFT occur within 30 day follow ICD implant . The long-term efficacy outcome composite fail first appropriate clinical ICD shock sudden death . This pilot study intend primarily confirm anticipated rate event demonstrate feasibility enrollment , statistical power determine intra-operative DFT testing associate significant short-term risk . If complication rate high predict enrollment feasible , large study would justify determine impact intra-operative DFT test long-term rate fail appropriated ICD shock sudden death . Events rate determine pilot study would use estimate sample size large study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>New York Heart Association ( NYHA ) Class II Left ventricular ejection fraction ( LVEF ) less equal 30 % multigated acquisition scan ( MUGA ) /catheterization OR LVEF le equal 30 % LV end diastolic dimension ≥ 60 mm ( echocardiogram ) within 6 month prior randomization Intrinsic QRS complex width ≥ 120 m OR pace QRS measurement ≥ 200 m ICD indication primary secondary prevention Optimal heart failure pharmacological therapy Normal sinus rhythm ; OR chronic persistent atrial tachyarrhythmia rest ventricular heart rate ≤ 60 beat per minute ( bpm ) 6 minute hall walk ventricular heart rate ≤ 90 bpm ; OR chronic persistent atrial tachyarrhythmia rest ventricular heart rate &gt; 60 bpm 6 minute hall walk ventricular heart rate &gt; 90 bpm book atrioventricular junction ablation . Intravenous inotropic agent last 4 day Patients life expectancy le one year noncardiac cause Expected undergo cardiac transplantation within one year ( status I ) In hospital patient acute cardiac noncardiac illness require intensive care Uncorrected uncorrectable primary valvular disease Restrictive , hypertrophic , reversible form cardiomyopathy Severe primary pulmonary disease cor pulmonale Tricuspid prosthetic valve Patients exist ICD ( patient exist pacemaker may include patient satisfy inclusion/exclusion criterion ) Coronary revascularization ( coronary artery bypass graft surgery [ CABG ] percutaneous coronary intervention [ PCI ] ) &lt; 1 month previously determine LVEF &gt; 30 % . Patients recent revascularization include previously determine LVEF ≤ 30 % . Patients acute coronary syndrome include myocardial infarction ( MI ) include patient previous MI LV dysfunction ( LVEF ≤ 30 % ) . Patients include another clinical trial affect objective study History noncompliance medical therapy Unable unwilling provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Congestive heart failure</keyword>
	<keyword>Multicentre randomize control trial</keyword>
	<keyword>Defibrillator</keyword>
	<keyword>Cardiac resynchronization</keyword>
	<keyword>Sudden death/mortality</keyword>
	<keyword>Hospitalization</keyword>
	<keyword>ICD indication</keyword>
	<keyword>NYHA Class II</keyword>
	<keyword>LVEF &lt; /equal 30 %</keyword>
	<keyword>QRS &gt; /equal 120 m</keyword>
</DOC>